Leerink Partners Starts Trillium Therapeutics (TRIL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
UPDATE: Cowen Starts Trillium Therapeutics (TRIL) at Outperform
April 27, 2015 8:19 AM EDT(Updated - April 27, 2015 10:02 AM EDT)
Cowen initiated coverage on Trillium Therapeutics (NASDAQ: TRIL) with an Outperform rating. Analyst Boris Peaker sees potential in the company's novel SIRPaFc molecule.
"Trillium Therapeutics is an early-stage biotechnology company whose lead asset, SIRPaFc is a novel... More
Trillium Therapeutics (TRIL) Gains as Cohen's Point72 Asset Shows New 5.6% Stake
April 23, 2015 5:08 PM EDTMomentum stock Trillium Therapeutics (NASDAQ: TRIL) is gaining after the close (+5.9%) after Steven Cohen's family office Point72 Asset Management, L.P. (formerly SAC Capital) disclosed a 5.6%, or 378,050 share, stake in the company. The firm did not hold shares... More
